Use of recombinant activated factor VII for bleeding in pancreatitis: A case series

Pancreas

Volumn 30, Issue 3, 2005, Pages 279-284

  Laffan, Mike A ^a   Tait, R Campbell ^b   Blatný, Jan ^c   Espersen, Kurt ^d   Grabowska, Izebelle ^e   Loch Bakoñska, Lidia ^f   Pauzkowska, Agata ^g   Stasiak Pikula, Elzbieta ^h   Michalska, Grazyna ^h   Wendon, Julia ⁱ   Piotrowska, Katarzyna ^j  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

^f Third Department of Surgery MC JU   (Poland)

^g MEDICAL UNIVERSITY OF WARSAW   (Poland)

^h POMERANIAN MEDICAL UNIVERSITY   (Poland)

ⁱ KING S COLLEGE HOSPITAL   (United Kingdom)

^j Department of Plastic Surgery   (Poland)

more..

Author keywords

Bleeding; Disseminated intravascular coagulation; Pancreatitis; Recombinant activated factor VII; Sepsis

Indexed keywords

HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ACUTE PANCREATITIS; ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HEMOSTASIS; HUMAN; INFECTION; MALE; PANCREATITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SEPSIS; THROMBOEMBOLISM; THROMBOSIS;

ADULT; AGED; BLOOD COAGULATION; BLOOD TRANSFUSION; CHILD, PRESCHOOL; FACTOR VII; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PANCREATITIS, ACUTE NECROTIZING; PANCREATITIS, CHRONIC; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 20144373407     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpa.0000158026.30925.b4     Document Type: Article

References (41)

1. Beckingham IJ, Bornman PC. ABC of diseases of liver, pancreas, and biliary system: acute pancreatitis. BMJ. 2001;322:595-598.
2. Bornman PC, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system: chronic pancreatitis. BMJ. 2001;322:660-663.
3. Banerjee AK, Kaul A, Bache E, et al. An audit of fatal acute pancreatitis. Postgrad Med. 1995;71:472-475.
4. Banks PA. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 1997;92:377-386.
5. Steinberg W, Tenner S. Acute pancreatitis. N Engl J Med. 1994;330:1198-1210.
6. Wilson C, Imrie CW. Changing patterns of incidence and mortality from acute pancreatitis in Scotland, 1961-1985. Br J Surg. 1990;77:731-734.
7. Beger HG, Rau B, Mayer J, et al. Natural course of acute pancreatitis. World J Surg. 1997;21:130-135.
8. Bhansali SK, Shah SC, Desai SB, et al. Infected necrosis complicating acute pancreatitis: experience with 131 cases. Indian J Gastroenterol. 2003;22:7-10.
9. Flati G, Salvatori F, Porowska B, et al. Severe hemorrhagic complication in pancreatitis. Ann Ital Chir. 1995;66:233-237.
10. Flati G, Andren-Sandberg A, La Pinta M, et al. Potentially fatal bleeding in acute pancreatitis: pathophysiology, prevention, and treatment. Pancreas. 2003;26:8-14.
11. Balthazar EJ, Fisher LA. Hemorrhagic complications of pancreatitis: radiologic evaluation with emphasis on CT imaging. Pancreatol. 2001;1:306-313.
12. Stabile BE, Wilson SE, Debas HT. Reduced mortality from bleeding pseudocysts and pseudoaneurysms causes by pancreatitis. Arch Surg. 1983;118:45-51.
13. Lusher JM, Roberts HR, Davignon G, et al. A randomised, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998;4:790-798.
14. Hedner U. NovoSeven® as a universal haemostatic agent. Blood Coagul Fibrinolysis. 2000;11:107-111.
15. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomized trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80:773-778.
16. Friederich PW, Wever PC, Briet E, et al. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol. 2001;66:292-294.
17. Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis. 1996;26(Suppl 1):159-164.
18. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost. 1998;80:352.
19. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology. 1997;113:1930-1937.
20. Hendriks HG, Meijer K, de Wolf JT, et al. Reduced transfusion requirements by recombinant Factor VIIa in orthotopic liver transplantation. Transplantation. 2001;71:402-405.
21. Martinowitz U, Kenet G, Lubetski A, et al. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anesth. 2002;49:S15-S20.
22. O'Neill PA, Bluth M, Gloster ES, et al. Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma. 2002;52:400-405.
23. Kenet G, Walden R, Eldad A, et al. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354:1879.
24. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet. 2003;361:201-205.
25. Al Douri MA, Shafi T, Al Khudairi DA, et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis. 2000;11(Suppl 1):S121-S127.
26. White B, McHale J, Ravi N, et al. Successful use of recombinant FVIIA (NovoSeven) in the management of intractable post surgical intra-abdominal haemorrhage. Br J Haematol. 1999;107:677-678.
27. Vlot AJ, Ton E, Mackaay AJ, et al. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. Am J Med. 2000;108:421-423.
28. Moscardó F, Pérez F, de la Rubia J, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol. 2001;114:174-176.
29. Blatt J, Gold SH, Wiley JM, et al. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant. 2001;28:405-407.
30. Chuansumrit A, Chantarojanasiri T, Isarangkura P, et al. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 2000;11(Suppl 1):S101-S105.
31. Tobias JD, Berkenbosch JW, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med. 2003;4:49-51.
32. Holcomb JB, Neville HL, Fischer CF, et al. Use of recombinant FVIIa for intraperitoneal coagulopathic bleeding in a septic patient. Curr Surg. 2003;60:423-427.
33. Svartholm E, Annerhagen V, Länne T. Treatment of bleeding in severe necrotizing pancreatitis with recombinant factor VIIa. Anesthesiology. 2002;96:1285-1286.
34. Schuster R, Lee SJ, Rink D. Treatment of bleeding in severe hemorrhagic pancreatitis with recombinant factor VIIa. Am Surg. 2003;69:1017-1018.
35. Roberts HR, Monroe DM, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol. 2004;41(Suppl 1):101-108.
36. Roberts H. Safety of treatment with NovoSeven®. Bloodline Rev. 2001;1:18-19. Available at: http://www.bloodline.net/stories/ storyReaders$3124.
37. Roberts HR. Recombinant factor VIIa (NovoSeven®) and the safety of treatment. Semin Hematol. 2001;38(Suppl):48-50.
38. NovoSeven Prescribing Information. Novo Nordisk Pharmaceuticals Inc., 2003.
39. Cid AR, Martinez J, Aznart JA, et al. Treatment with recombinant activated factor VII of intra-abdominal bleeding associated with disseminated intravascular coagulation cause by septic shock. J Thromb Haemost. 2003;1(Suppl 1):0606.
40. Tobias JD, Berkenbosch JW, Muruve NA, et al. Correction of coagulopathy using recombinant factor VII before removal of an intra-aortic balloon pump. J Cardiothorac Vasc Anesth. 2002;16:612-614.
41. Tobias JD, Groeper K, Berkenbosch JW. Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients. South Med J. 2003;96:12-16.